Oncotarget, Author at Oncotarget

Oncotarget News

Behind the Study: Molecular Dialogue Between Tumor Cells and Fibroblasts

May 25, 2023

Dr. Gopal C. Kundu from KIIT Deemed to be University in Odisha, India, describes a recent editorial he co-authored that was published by Oncotarget in Volume 14, entitled, “The molecular... read more

Oncotarget

Behind the Study: Role of Biomarkers in Management of Lumps in the Breast

May 10, 2023

Dr. Georg F. Weber, from the University of Cincinnati Academic Health Center, describes a recent research perspective he authored that was published by Oncotarget in Volume 14, entitled, “Crossroads: the... read more

“Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention.”

Oncotarget

Behind the Study: APOE Genotype Determines Cancer Patients Most Likely to Benefit From Exercise

December 13, 2022

Dr. Kerri Winters-Stone and Dr. Jacob Raber from Oregon Health and Science University, describe a research paper they co-authored that was published by Oncotarget in Volume 13, entitled, “Association of... read more

Oncotarget

Behind the Study: Inhibition of Resistant Triple-negative Breast Cancer Cells

September 19, 2022

Dr. Balraj Singh from the University of Texas MD Anderson Cancer Center, describes a recent research paper he co-authored that was published by Oncotarget, entitled, “Inhibition of resistant triple-negative breast... read more

Dr. Glenn Simmons Jr. and Dr. Stefani Thomas

Oncotarget

Behind the Study: Targeting Lipid Metabolism in Treatment of Ovarian Cancer

September 12, 2022

Dr. Glenn Simmons Jr. from Cornell University College of Veterinary Medicine, and Dr. Stefani Thomas from University of Minnesota School of Medicine, detail a recent review they co-authored that was... read more

Oncotarget

Behind the Study: Molecular Characterization of Lung Carcinomas Expressing KK-LC-1

July 11, 2022

Dr. Robert Hsu from the University of Southern California, Norris Comprehensive Cancer Center, describes a recent research paper he co-authored that was published by Oncotarget, entitled, “Molecular characterization of... read more

Oncotarget

Behind the Study: IGF-pathway Biomarkers and Lung Cancer

June 14, 2022

Dr. Alexander Pohlman from Rush Medical College, Rush University Medical Center, Chicago, IL, describes a recent review published by Oncotarget that he co-authored entitled, “The role of IGF-pathway biomarkers in... read more

Figure 3: Similar gene expression patterns between endocrine-resistant breast cancer and triple-negative breast cancer.

Oncotarget

Novel Group of Genes That Cause Endocrine Resistance in Breast Cancer Identified by Dynamic Gene Expression Analysis

June 8, 2022

Our findings identify 34 novel genes for further study as potential therapeutic targets for treatment of endocrine-resistant BC and TNBC.”BUFFALO, NY- June 8, 2022 – A research paper was recently... read more

CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling

Oncotarget

Anti-Cancer Drug Profiling With CancerOmicsNet

May 19, 2022

BUFFALO, NY- May 19, 2022 – A new research paper was published in Volume 13 of Oncotarget, entitled, “CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling.”Researchers from Louisiana State... read more

Oncotarget

Testimonial: Dr. Mark Woodford

May 3, 2022

Dr. Mark Woodford, Assistant Professor at the Department of Urology, SUNY Upstate Medical University, Syracuse, NY, describes his experience publishing the meeting report, “Seventh BHD international symposium: recent scientific and... read more